1. Home
  2. GBIO vs TENX Comparison

GBIO vs TENX Comparison

Compare GBIO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • TENX
  • Stock Information
  • Founded
  • GBIO 2016
  • TENX 1967
  • Country
  • GBIO United States
  • TENX United States
  • Employees
  • GBIO N/A
  • TENX N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • TENX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBIO Health Care
  • TENX Health Care
  • Exchange
  • GBIO Nasdaq
  • TENX Nasdaq
  • Market Cap
  • GBIO 29.5M
  • TENX 25.0M
  • IPO Year
  • GBIO 2020
  • TENX N/A
  • Fundamental
  • Price
  • GBIO $6.00
  • TENX $5.99
  • Analyst Decision
  • GBIO Buy
  • TENX Strong Buy
  • Analyst Count
  • GBIO 4
  • TENX 3
  • Target Price
  • GBIO $10.67
  • TENX $15.00
  • AVG Volume (30 Days)
  • GBIO 792.1K
  • TENX 15.7K
  • Earning Date
  • GBIO 08-12-2025
  • TENX 08-13-2025
  • Dividend Yield
  • GBIO N/A
  • TENX N/A
  • EPS Growth
  • GBIO N/A
  • TENX N/A
  • EPS
  • GBIO N/A
  • TENX N/A
  • Revenue
  • GBIO $21,230,000.00
  • TENX N/A
  • Revenue This Year
  • GBIO N/A
  • TENX N/A
  • Revenue Next Year
  • GBIO N/A
  • TENX N/A
  • P/E Ratio
  • GBIO N/A
  • TENX N/A
  • Revenue Growth
  • GBIO 61.15
  • TENX N/A
  • 52 Week Low
  • GBIO $3.00
  • TENX $3.25
  • 52 Week High
  • GBIO $29.40
  • TENX $7.89
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 57.46
  • TENX 51.19
  • Support Level
  • GBIO $5.91
  • TENX $5.88
  • Resistance Level
  • GBIO $6.48
  • TENX $6.02
  • Average True Range (ATR)
  • GBIO 0.50
  • TENX 0.14
  • MACD
  • GBIO -0.03
  • TENX -0.01
  • Stochastic Oscillator
  • GBIO 68.12
  • TENX 70.37

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: